Skip to main content
Naresh Bumma, MD, Oncology, Columbus, OH, The OSUCCC - James

NareshBummaMD

Oncology • Columbus, OH

Hematologic Oncology

Assistant Professor, Hematology

Join to view full profile

Dr. Bumma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bumma's full profile

Already have an account?

Summary

  • Dr. Naresh Bumma is an oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute and Ohio State University Wexner Medical Center.

Education & Training

  • All India Institute of Medical Sciences
    All India Institute of Medical SciencesClass of 2011
  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2025
  • MI State Medical License
    MI State Medical License 2015 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Second Prize, Poster Presentation Michigan Association of Physicians from India, 2017
  • Third Prize, Poster Presentation Michigan Association of Physicians from India, 2017
  • Prize for Oral Presentation Annual KCI Junior Faculty Trainee Research Retreat, 2017
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Daratumumab proves safe and highly effective in AL amyloidosis  
    Khouri, J., Kin, A., Thapa, B., Reu, F. J., Bumma, N., Samaras, C. J., ... & Faiman, B. M., British journal of haematology, 1/1/2018
  • Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers  
    Jeyakumar, G., Bumma, N., Kim, S., Landry, C., Kim, H., Silski, C., ... & Vaishampayan, U. N., Journal of Clinical Oncology, 1/1/2017
  • Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia  
    Bumma N, Papadantonakis N, Advani S.A., Future Oncology, 1/1/2015
  • Join now to see all

Abstracts/Posters

  • The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
    Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
    Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
    Naresh Bumma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+)-Negative Stage II-III... 
    Detroit, MI - 1/11/2017
  • Once weekly subcutaneous bortezomib based induction therapy in AL amyloidosis 
    Indianapolis, IN - 1/27/2014

Press Mentions

  • Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-Treated Multiple Myeloma
    Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-Treated Multiple MyelomaDecember 13th, 2022

Hospital Affiliations

Dr. Naresh Bumma, Dr. Naresh Bumma, MD, Dr. N Bumma